Please assess the completion status of the following clinical trial:

Trial Title: Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be 18 years of age or older~2. Patients must present to clinic with a diagnosis of benign prostatic hyperplasia with lower urinary tract symptoms~3. Patients must be scheduled to undergo a holmium laser prostate surgery (enucleation or ablation)~Exclusion Criteria:~1. Patients who are under 18 years of age are not eligible.~2. Patients who have a diagnosis of bladder cancer are not eligible.~3. Patient who have a diagnosis of prostate cancer are not eligible.~4. Patients with an elevated prostate-specific antigen (PSA) suggesting prostate cancer are not eligible unless patient has prior negative prostate biopsy.~5. Patients who have acute prostatitis, a prostate abscess, or neurogenic bladder are not eligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Long Term Medication Usage (Type: None): Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
- Short Term Medication Usage (Type: None): Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)

Based on this trial design, predict the completion outcome and termination type (if applicable).